Received Sep 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
soreness at the site; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site pain in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included shingles. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: soreness at the site). The outcome of the injection site pain was resolved. The reporter considered the injection site pain to be related to Shingrix. The company considered the injection site pain to be related to Shingrix. Additional Information: GSK Receipt Date: 24-SEP-2025 The patient only had arm soreness at the site with the first one, like a tetanus shot, so she was not prepared. The patient have since learned it was very common and just shows that it was working by stimulating immune response. Having had three bouts of shingles that progressively got worse, the one day of discomfort was worth it. This case is linked with US2025AMR124606, reported by same reporter.; Sender's Comments: US-GSK-US2025AMR124606:same reporter US-GSK-US2025AMR124423:same reporter diff dose US-GSK-US2025AMR124422:same reporter diff dose
Medical History/Concurrent Conditions: Shingles
Test Name: Body temperature; Result Unstructured Data: (Test Result:100,Unit:degree F,Normal Low:,Normal High:)